RxDoctor Payments Data

Nader Oskooilar

Psychiatry · Newport Beach, CANPI 1336144872

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 36 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by AbbVie at 56.4% of the total.

$840in general payments, 2019–2025

Across 36 payments — averaging $23.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$474
  • Adlon Therapeutics L.p.$143
  • Neuronetics, Inc.$137
  • Sunovion Pharmaceuticals Inc.$41
  • Vanda Pharmaceuticals Inc.$27
  • Johnson & Johnson$18
$3,332,382in research payments, 2019–2025

Across 749 payments — averaging $4449.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$815K
  • Eli Lilly$444K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$275K
  • Supernus Pharmaceuticals, Inc.$246K
  • Pfizer$246K
  • Genentech, Inc.$229K
  • plus $1.1M from 10 others

What the payments were for

  • Food & beverage$840100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$840 in reported general payments places this provider in the 70th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
Paroxetine ErParoxetine Hcl11$795
Methylphenidate Hcl18$776
Olanzapine22$337
Escitalopram Oxalate14$132

Paid to pharmacies, not to this prescriber.

Other psychiatry in Newport Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →